Company
Oncusp Therapeutics
OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments to deliver hope to cancer patients worldwide.
Also known as OnCusp Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Princeton, United States
- Founded
- 2021
- Legal name
- OnCusp Therapeutics, Inc.
- oncusptx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Record updated 28 September 2026
About
OnCusp Therapeutics, Inc. is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building biotech startups, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
Funding snapshot
- Total raised
- $139MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $100M2024-01-04
Funding rounds
- Series A
- $100M2024-01-04, Company stated
- Seed extension
- $14M2022-08, Company stated
- Seed
- $25M2021-04, Company stated